

RAPID DIAGNOSTICS

Modelling the cost-effectiveness of introducing rapid syphilis tests into an antenatal syphilis screening programme in Mwanza, Tanzania

P Vickerman, R W Peeling, F Terris-Prestholt, J Changalucha, D Mabey, D Watson-Jones, C Watts

Sex Transm Infect 2006;**82**(Suppl V):v38–v43. doi: 10.1136/sti.2006.021824

See end of article for authors' affiliations

Correspondence to: Dr Peter Vickerman, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; peter.vickerman@lshtm.ac.uk

Accepted 4 September 2006

Objectives: A study found screening (with rapid plasma reagin (RPR)) pregnant women for maternal syphilis was cost-effective in Mwanza, Tanzania. Recently, four rapid point-of-care (POC) syphilis tests were evaluated in Mwanza, and found to have reasonable sensitivity/specificity. This analysis estimates the relative cost-effectiveness of using these POC tests in the Mwanza syphilis screening intervention.

Methods: Empirical cost and epidemiological data were used to model the potential benefit of using POC tests instead of RPR. Reductions in costs relating to training, supplies, and equipment were estimated, and any changes in impact due to test sensitivity were included. Additional modelling explored how the results vary with prevalence of past infection, misclassified RPR results, and if not all women return for treatment.

Results: The cost-effectiveness of using POC tests is mainly dependent on their cost and sensitivity for high titre active syphilis (HTAS). Savings due to reductions in training and equipment are small. Current POC tests may save more disability-adjusted life years (DALYs) than the RPR test in Mwanza, but the test cost needs to be <US\$0.63 to be as cost-effective as RPR. However, the cost-effectiveness of the RPR test worsens by 15% if its HTAS sensitivity had been 75% instead of 86%, and by 25–65% if 20–40% of women had not returned for treatment. In such settings, POC tests could improve cost-effectiveness. Lastly, the cost-effectiveness of POC tests is affected little by the prevalence of syphilis, false RPR-positives, and past infections.

Discussion: Although the price of most POC tests needs to be reduced to make them as cost-effective as RPR, their simplicity and limited requirements for electricity/equipment suggest their use could improve the coverage of antenatal syphilis screening in developing countries.

Many developing countries continue to have high syphilis prevalences,¹ with maternal syphilis contributing to substantial perinatal morbidity and mortality worldwide.² However, even though antenatal syphilis screening can avert these adverse pregnancy outcomes,³ and is cost-effective,^{4–8} less than 40% of women attending antenatal services in sub-Saharan Africa receive syphilis screening and treatment.^{6–9,12}

The low screening and treatment coverage is partly due to limitations of the rapid plasma reagin (RPR) test: it is only useable on serum, requires refrigeration, and has low accuracy in settings with insufficient training or facilities.^{10–13,14} In addition, long delays between testing and treatment due to batch testing, waiting for serum to separate, or sending tests to central laboratories result in many women not returning/staying for treatment.^{6,10,15} In light of this, the Sexually Transmitted Diseases Diagnostics Initiative (SDI) in the World Health Organization (WHO) has promoted the development, evaluation and application of simple rapid point-of-care (POC) tests for diagnosing syphilis in resource-constrained settings.¹⁶ In so doing, it was hoped a test would be developed that could help increase the coverage of antenatal screening and treatment in sub-Saharan Africa.

In 2002, six commercially available POC tests were evaluated by SDI.¹⁶ The evaluated tests were similar to treponemal tests (*Treponema pallidum* haemagglutination assay (TPHA) or *Treponema pallidum* particle agglutination assay (TPPA)) in that they are highly specific, but once positive, they remain so for life.¹⁶ RPR, in contrast, mainly detects syphilis infection, but is not very specific.^{17,18} However, there are a number of advantages to the new POC tests when compared to RPR and/or TPHA/TPPA: they require less or no equipment, minimal training and support, are easier to read, remain stable at room

temperature, and can be used on whole blood. This has raised the question of whether these more expensive POC tests could improve existing antenatal syphilis screening programmes.

A previous study in Mwanza, Tanzania, found screening (with RPR) and treating pregnant women for maternal syphilis was highly cost-effective for averting adverse birth outcomes.⁴ To explore the potential role of POC tests in antenatal syphilis screening interventions, this paper uses data from this study and an SDI evaluation of four syphilis POC tests in Mwanza¹⁹ to model the cost-effectiveness of using POC tests in this intervention. The model first compared the projected cost-effectiveness of using POC tests with the current RPR screening strategy used in Mwanza, and then explored how the results would vary in settings: with different levels of past infection; where the RPR test is less accurate; or where fewer women receive treatment due to delays between testing and treatment.

METHODS

Cost-effectiveness of intervention with RPR test

From July 1998 to June 1999, 9713 women were screened for maternal syphilis at the antenatal clinic in Mwanza, of which 696 (7.2%) were RPR positive and treated. The number of women treated for high titre active syphilis (HTAS) (RPR \geq 1:8 and TPHA positive), the only stage shown to be associated with adverse birth outcomes in this setting,²⁰ was estimated to be 187.^{3,21} However, 30 cases were missed due to the clinic RPR

Abbreviations: ANC, antenatal clinic; DALY, disability-adjusted life year; HTAS, high titre active syphilis; POC, point-of-care; RPR, rapid plasma reagin; SDI, Sexually Transmitted Diseases Diagnostics Initiative; TPHA, *Treponema pallidum* haemagglutination assay; TPPA, *Treponema pallidum* particle agglutination assay; WHO, World Health Organization

test having a lower sensitivity for HTAS (86.2%) than the laboratory based RPR test used to assess its accuracy.²¹ The impact of the intervention was estimated in terms of disability-adjusted life years (DALYs) saved, where DALYs are defined as the sum of years of life lost due to premature mortality and years lived with disability adjusted for severity. Based on the detailed calculations by Terris-Prestholt *et al*⁴ and only considering adverse birth outcomes, this intervention saved 1321 DALYs (7.1 DALYs saved per HTAS case treated) if stillbirth is considered a full life lost and the Tanzanian life expectancy is used, at an economic cost of US\$12.0 per DALY saved (2005 US\$). In this analysis, modelling is used to estimate how the cost-effectiveness of this intervention would have changed if they had used syphilis POC tests over this period.

Effectiveness of intervention with POC test

This study only considers the impact achieved from averting adverse birth outcomes. For this reason, and because only HTAS has been shown to be associated with adverse birth outcomes in this setting,²⁰ the impact analysis is only concerned with the number of HTAS treated when different POC tests are used.

In Mwanza, some HTAS cases were not treated because of the reduced sensitivity of the clinic RPR test.²¹ If the TPHA test had been used then all HTAS cases could have been diagnosed and treated.²⁰ As with the TPHA test, all available syphilis POC tests are treponemal specific, but have reduced sensitivity compared to the TPPA/TPHA test when used on serum.¹⁶ If the sensitivity (S_r) and specificity (Sp_r) of the POC test compared to TPHA is known, the number of women that would test positive with a POC test (N_r) can be estimated from the number positive with the TPHA test (N_{TPHA}):

$$N_r = N_{TPHA}S_r + (1 - Sp_r)(N - N_{TPHA}) \quad \text{Equation 1}$$

where N is the number of women screened. If the ratio between the TPHA and RPR prevalence is known (θ) then the number that will test positive with a POC test can be estimated from the number testing RPR positive (N_{RPR}) in laboratory conditions by adapting equation 1:

$$N_r = \theta N_{RPR}S_r + (1 - Sp_r)(N - \theta N_{RPR}) \quad \text{Equation 2}$$

Because of their reduced sensitivity, POC tests may not diagnose all HTAS cases, with the number positive (N_r^{Hi}) being:

$$N_r^{Hi} = N^{Hi}S_r^{Hi} \quad \text{Equation 3}$$

where N^{Hi} is the number of HTAS cases in the screened population and S_r^{Hi} is the sensitivity of the POC test for HTAS. Because all RPR positive women were treated by the Mwanza intervention, equations 2 and 3 can be used to estimate the number of women and HTAS cases that would have been treated with the POC test in Mwanza. Using the data presented by Terris-Prestholt *et al*⁴ on the DALYs saved per HTAS case treated ($DALY_{tan}$), this can then be used to estimate the DALYs saved.

Cost of intervention with POC test

From the study by Terris-Prestholt *et al*,⁴ a cost function for the total economic cost of the existing intervention using RPR tests can be obtained:

$$COST_{RPR} = ST + (E_s + E_c + E_f) + T + (\Delta_d + \Delta_r + \Delta_o) + (P_i + P_o) + R \quad \text{Equation 4}$$

where all variables are defined in table 1. This cost function was adapted to model the costs of using POC tests (2005 US\$). The model assumed the following aspects of the screening intervention would have changed if POC tests had been used: lab personnel would have required less training; less or no equipment would have been needed; and the number of

women treated would have changed depending on the sensitivity/specificity of the POC tests. Therefore, the cost of using POC tests ($COST_r$) is estimated as:

$$COST_r = ST + (E_s \delta E) + T \delta T + (\Delta_d^r + \Delta_r^r + \Delta_o) + (P_i \delta P + P_o) + R \delta R \quad \text{Equation 5}$$

where most parameters are defined as before, although E_s and E_f are not needed because POC tests do not require a shaker or fridge, and Δ_r^r and Δ_d^r are the test and drug costs when using POC tests:

$$\Delta_r^r = C_r N (1 + \delta W) \quad \text{Equation 6}$$

$$\Delta_d^r = C_{drug} [N_{RPR} \theta S_r + (1 - Sp_r)(N - N_{RPR} \theta)] \quad \text{Equation 7}$$

where C_{drug} is the penicillin cost per woman treated, C_r is the POC test cost, and δW is the relative wastage of POC tests.

Model parameters

The model was mainly parameterised using data from three studies undertaken in Mwanza, with uncertainty ranges being assigned to most model inputs (table 1). Cost and intervention output data were obtained for 1998–1999 from Terris-Prestholt *et al*.⁴ Data on the accuracy of the clinic RPR test compared to the RPR test undertaken at a reference laboratory (table 1), and the number of screened women that would have tested positive with a laboratory based RPR or TPHA test, were obtained from a prospective cohort study undertaken in 1997–1999.^{3, 21}

Lastly, sensitivity/specificity estimates for the four syphilis POC tests when compared to the TPPA test undertaken in a laboratory setting were obtained from an evaluation of these tests undertaken in Mwanza in 2004¹⁹ (table 1 and appendix 1: to view appendices 1-6 visit the *STI* website—<http://www.stijournal.com/supplemental>). The tests were evaluated on blood in an antenatal clinic (ANC) setting and on blood and serum in a laboratory setting. The ANC results were used to estimate the impact of using POC tests on blood, and because of a lack of other data the laboratory results were used to estimate the impact of using the tests on serum. The sensitivity of the tests for HTAS was also evaluated, but only on 13–20 HTAS samples. Table 1 also includes the current WHO procurement cost for the POC tests. The POC tests were also assumed to need less training and supply deliveries, and no centrifuge was needed if the tests were used on whole blood.

Cost-effectiveness of intervention with POC test

Using equations 3 and 5, the cost-effectiveness of using a specific POC test (CE_r) can be estimated by dividing the estimated cost of the intervention while using that POC test by projections of the DALYs saved from averting adverse birth outcomes:

$$CE_r = \frac{COST_r}{N_r^{Hi} DALY_{tan}} \quad \text{Equation 8}$$

Because of uncertainty in many model inputs, an uncertainty analysis was undertaken on the projected cost ($COST_r$) and impact (N_r^{Hi}) of using each POC test. Uniform distributions were associated with the uncertainty intervals for most model parameters except the sensitivity and specificity of the POC tests which were assumed to be normally distributed. For each test, random sampling of the parameter uncertainty ranges was used to obtain 500 parameter sets. These produced paired estimates for the impact and cost of the intervention. The distribution obtained was used to obtain uncertainty bounds for the intervention’s cost-effectiveness, which was compared to the cost-effectiveness of the RPR test.⁴ A multi-linear regression analysis was then undertaken to determine which parameters contributed most to the uncertainty in the cost-effectiveness projections.

Table 1 Model parameters for estimating the cost-effectiveness of the POC test. Cost estimates are in 2005 US\$

Model parameters	Symbol	Value used	Reference/source
Cost parameters for RPR intervention			
Start up cost	ST	\$ 760.0	4
Shaker cost	E_s	\$ 111.3	4
Centrifuge cost	E_c	\$ 171.8	4
Fridge cost	E_f	\$ 69.0	4
Training cost	T	\$ 125.9	4
Total drug cost	Δ_d	\$ 409.2	4
Total RPR test cost	Δ_t	\$ 3640.7	4
Cost of other supplies	Δ_o	\$ 4509.0	4
Cost of laboratory staff	P_l	\$ 2156.3	4
Cost of medical and other staff	P_o	\$ 3720.4	4
Cost of transport for requisitions	R	\$ 158.0	4
Total cost of intervention	$COST_{RPR}$	\$ 15,831.2	4
Additional cost parameters for POC test intervention			
Cost per POC test	C_r	Bioline \$0.47, Syphchek and Visitect \$0.75, Determine \$1.00	Cost through WHO in 2005
Cost of penicillin per woman treated	C_{drug}	\$0.426	Cost for 1998 inflated to 2005 ⁴
Impact model parameters			
Number of woman screened from 1998–1999	N	9713	4
Number of screened women positive with RPR test at ANC clinic from 1998–1999		696	4
Estimated number of women positive with RPR test at reference laboratory clinic N_{RPR}		1021	Estimated using clinic RPR test sensitivity (61.8%) and specificity (99.3%) from cohort study ^{4, 21} (see appendix 2)
Sensitivity of RPR test used at clinic for HTAS	S_{RPR}^{Hi}	86.2%	3, 21
Sensitivity of syphilis POC tests:			
For all syphilis	S_r	45.8–97.1%	See appendix 1 for more details ¹⁹
For HTAS	S_r^{Hi}	64.0–100%	See appendix 1 for more details ¹⁹
Specificity of syphilis POC tests	S_{p_r}	93.4–99.9%	See appendix 1 for more details ¹⁹
Ratio of TPPA/TPHA to RPR prevalence when tests undertaken in reference laboratory	θ	95.5% (85–107%)	Estimated from cohort study ^{3, 21}
Whether they need centrifuge?	δE	0 if use blood, 1 if use serum	All POC tests can be used on blood ¹⁶
Relative time needed for training compared to RPR test	δT	50–100%	Assume less training needed for POC test because simpler to use and diagnose
Relative number of requisitions needed for POC test	δR	10–50%	53 requisitions done per year for RPR. Less needed for POC tests because no fridge needed and stable for > 1 year ¹⁶
Relative amount of wastage	δW	0–5%	No specific data

ANC, antenatal clinic; HTAS, high titre active syphilis; POC, point-of-care; RPR, rapid plasma reagin; TPHA, *Treponema pallidum* haemagglutination assay; TPPA, *Treponema pallidum* particle agglutination assay.
To view appendices 1 and 2 visit the STI website— <http://www.stijournal.com/supplemental>

Threshold cost of POC test

The threshold cost (C_r^*) at which a POC test becomes as cost-effective as the RPR test can be obtained from equation 8 to give (see appendix 3 for the derivation):

$$C_r^* = \frac{1}{N(1 + \delta W)} \left[\frac{S_r^{Hi}}{S_{RPR}^{Hi}} COST_{RPR} - (COST_r - \Delta_t^r) \right] \quad \text{Equation 9}$$

For each POC test, the cost-threshold was calculated for different HTAS sensitivities while other parameters were varied to obtain the lowest cost-threshold at that sensitivity.

Sensitivity analysis to generalise to other settings

To generalise the results of this analysis to other settings, the effect of variations in key parameters on the cost-effectiveness of using the RPR or Bioline test (on blood) was explored.

Firstly, many women screened with the RPR test do not receive treatment at their initial visit^{6, 11, 12, 15, 22} or do not wait long enough for treatment, and so the cost-effectiveness of the RPR test was estimated for different return rates (60–80%).^{6, 10, 11, 22} Secondly, because of the difficulty in interpreting RPR test results in clinic settings^{11, 13, 14} and the frequent occurrence of RPR biological false positives,^{13, 17, 18, 23} the cost-effectiveness of the RPR test was estimated for different

sensitivities to HTAS (75–100%),^{11, 14} and for different prevalences of biological false positives (N_{RPR} was varied between 563–1301^{13, 17}). In contrast, the cost-effectiveness of the POC test was estimated for different prevalences of old infection by varying the ratio θ between 104–188%.^{17, 24, 25} Lastly, the cost-effectiveness of both tests was estimated for a wide range of syphilis prevalences (5–21%).

The combined effect of these sensitivity analyses on the cost-threshold for each POC test was analysed by incorporating the return rate for the RPR test into equation 9.

RESULTS

Cost-effectiveness of POC tests

The estimated cost-effectiveness of using the four syphilis POC tests on whole blood or serum are shown in table 2. The results show that all POC tests, except the Determine test, will on average result in more DALYs saved from averting adverse birth outcomes than the RPR test. This is due to their higher sensitivity for HTAS. However, because of the high cost of each POC test, they all result in higher costs, about 6% greater with Bioline test, 21–23% with Visitect and Syphcheck tests, and 36–39% with Determine test. This results in all POC tests, except Bioline, being less cost-effective than the RPR test (ranging from 15–41% higher cost per DALY saved than RPR). In contrast, although our projections suggest the Bioline test is on

Table 2 Cost-effectiveness per DALY saved (2005 US\$) of each POC test using Tanzanian life expectancy. Uncertainty bounds are in brackets

POC test	Test done on serum*			Test done on blood†		
	DALYs saved	Cost/DALY saved	% of RPR cost/DALY saved	DALYs saved	Cost/DALY saved	% of RPR cost/DALY saved
RPR test	1321	12.0	100%			
Determine (Abbot)	1316 (746–1532)	17.0 (14.3–29.5)	141% (119–247%)	1309 (681–1529)	16.8 (14.0–31.5)	140% (117–263%)
Visitect (Omega)	1373 (877–1532)	14.3 (12.6–22.4)	119% (105–187%)	1373 (935–1531)	14.1 (12.4–20.7)	118% (104–173%)
Syphcheck (Qualpro)	1390 (887–1531)	14.1 (12.6–21.9)	118% (105–183%)	1397 (972–1532)	13.9 (12.5–19.7)	116% (104–164%)
Bioline (Standard)	1430 (1127–1532)	11.8 (10.9–15.0)	99% (91–125%)	1372 (914–1530)	12.1 (10.7–18.1)	101% (89–151%)

*The impact and cost-effectiveness estimates for when the POC test is done on serum use sensitivity and specificity estimates derived from the reference laboratory.

† The impact and cost-effectiveness estimates for when the POC test is done on blood use sensitivity and specificity estimates derived from antenatal clinic.

DALY, disability-adjusted life year; POC, point-of-care; RPR, rapid plasma reagin.

average more cost-effective than RPR, 49% of the simulations from the uncertainty analysis suggest otherwise (when used on blood). This is highlighted in appendix 4, which shows the incremental (additional) cost and effectiveness of each POC test relative to the RPR test from the uncertainty analysis. The plots show that there is substantial uncertainty in the incremental impact of the POC tests, but little variation in the incremental cost.

When a multi-linear regression analysis was undertaken on the input and output from each uncertainty analysis, the variability in the cost-effectiveness of each POC test was found to be mainly dependent on the uncertainty in the sensitivity of the POC tests for HTAS. This is illustrated in fig 1, and shows that for each 5% increase in the sensitivity of the POC tests there is an approximate \$1 improvement in their cost-effectiveness ratio.

Cost-effectiveness of RPR and POC tests in other settings

A sensitivity analysis was undertaken to explore how the cost-effectiveness of the RPR or POC test changes between settings. The results showed that the prevalence of syphilis, past infections, or RPR false positives has little effect on the




Figure 1 Projected cost-effectiveness (per disability-adjusted life year (DALY) saved in 2005 US\$) of each syphilis point-of-care (POC) test for different assumptions about their sensitivity for high titre active syphilis (HTAS). The projections assume that the tests are used on blood in an antenatal clinic setting and the bounds refer to the variability due to the uncertainty in the other parameters. CE, cost-effectiveness; RPR, rapid plasma reagin.

cost-effectiveness projections. In contrast, the cost-effectiveness of the RPR test worsens by 15% if its sensitivity for HTAS had been 75% instead of 86%, and by 25–65% if 20–40% of women had not returned for treatment. In these two scenarios, the Bioline POC test is highly likely to be more cost-effective than the RPR test, whereas the other POC tests will only be more cost-effective if the return rate for treatment is towards the lower end of the range considered or their sensitivity for HTAS is towards the high end of the estimated confidence intervals. In contrast, if the RPR test’s sensitivity for HTAS had been 100% then the cost-effectiveness of the RPR test would have improved by 14%. In this situation, the POC tests will only be as cost-effective as the RPR test if they are much cheaper than their current cost, or not all women return for treatment with the RPR test. Appendix 6 shows how the cost-effectiveness of using the RPR or Bioline test changes for these specific scenarios.

Cost thresholds for POC tests

The results in fig 1 show that at current prices only the cheapest POC test (Bioline) could be as cost-effective as the RPR test in Mwanza. Indeed, if they are 100% sensitive for HTAS, the cost of the POC tests has to be less than \$0.63 for their cost-effectiveness to be similar to the RPR test. However, if the sensitivity of the POC tests is only 85%, then even the Bioline test would have to be at least \$0.13 cheaper than its current cost (\$0.47). Appendix 5 shows the threshold costs for each POC test, and shows that for a specific HTAS sensitivity, the cost-thresholds only vary by \$0.04 between tests and whether they are used on blood or serum.

For different POC and RPR test sensitivities and return rates, fig 2 shows the lower-bound cost-thresholds for the POC tests. The dashed line signifies the projections for Mwanza (RPR test sensitivity for HTAS = 86%). The figure shows that for every 5% decrease in the return rate or sensitivity of the RPR test for HTAS, the cost of a POC test can be about \$0.10 greater. In contrast, for every 5% decrease in the sensitivity of the POC test for HTAS, its cost has to decrease by about \$0.12.

DISCUSSION

This study compared the likely cost-effectiveness of four syphilis POC tests against the cost-effectiveness of the RPR test in an antenatal syphilis screening intervention in Mwanza, Tanzania. Uncertainty in the POC test sensitivity for HTAS resulted in uncertainty in their likely impact and cost-effectiveness. Despite this uncertainty, the model projections suggest that all the POC tests, except Determine, are likely to result in marginally greater impact than the RPR test due to their higher HTAS sensitivity in this setting. However, at




Figure 2 Threshold costs (in 2005 US\$) for POC test to be as cost-effective as RPR test for different sensitivities of POC and RPR test for HTAS and different return rates for treatment with the RPR test. Dashed line signifies the cost thresholds for Mwanza. HTAS, high titre active syphilis; POC, point-of-care; RPR, rapid plasma reagin.

current prices, only the Bioline test may be as cost-effective, and will at best result in an 11% improvement in the cost-effectiveness ratio (at 100% HTAS sensitivity). In contrast, the other POC tests need to be 33–50% cheaper to be as cost-effectiveness as the RPR test. For example, if the POC tests are 95% sensitive for HTAS, then they would need to cost ~\$0.54 per test (if used on blood), whereas for each 5% reduction in sensitivity the price of the POC tests need to drop by about \$0.10. These results illustrate that only Bioline can be considered as a replacement for RPR in Mwanza, and highlights the importance of HTAS sensitivity on threshold prices for POC tests.

The antenatal clinic in Mwanza was well equipped with a centrifuge, electric shaker and refrigerator. This meant the RPR test could be done relatively quickly on-site, and all women were tested and treated during the same visit. In other less well equipped clinics, or in settings without electricity, blood samples are sometimes sent to central laboratories for testing, or are left to stand to separate the serum needed for RPR testing. These delays can result in up to 20–40% of screened women not receiving treatment.^{7 10–12} In these settings the model projects the cost-effectiveness of using the RPR test could worsen by 25% and 65% for an 80% and 60% return rate, respectively. Even at the cheaper of these cost-effectiveness levels, it is highly likely that the Bioline test will be more cost-effective than the RPR test, whereas the Syphcheck and Visitect tests will be more cost-effective if their sensitivity to HTAS is greater than 80%. This illustrates the usefulness of POC tests in resource poor settings, because they can be used on whole blood, and do not require electrical equipment.

The sensitivity of the RPR test used at the Mwanza clinic was quite low for HTAS (86.2%). Had the intervention achieved 100% sensitivity, the intervention's cost-effectiveness would have improved by 14%, and none of the POC tests would have

been more cost-effective at current prices. This illustrates that the RPR test is likely to be the best choice in settings with good facilities and well trained staff. However, the conditions for undertaking the RPR test will be far from perfect in many clinics in developing countries.^{10 13} If the RPR test had been 75% sensitive for HTAS,¹⁴ then the Bioline test would be more cost-effective if its HTAS sensitivity is above 80%, whereas the Visitect and Syphcheck tests would need an HTAS sensitivity above 95%. All the POC tests would be more cost-effective if the RPR test had a HTAS sensitivity below 65%. This again illustrates the benefit of using POC tests in settings that are not ideal for the RPR test.

Another important question is whether our results would vary in other epidemiological settings. However, although this analysis showed that the cost-effectiveness of each test is highly dependent on syphilis prevalence, the relative cost-effectiveness of the POC tests compared to RPR is not. This implies that syphilis prevalence should not be used as a decision criterion for using either type of test.

One weakness of current POC tests is that individuals remain positive after resolution of infection. This means their use could result in substantial over-treatment, especially if syphilis treatment has been occurring.^{17 18 24 25} Similarly biological false positive RPR results can also result in substantial over-treatment.^{17 18 23} However, apart from the possible negative social implications of wrongly diagnosing women for syphilis,²⁶ this analysis showed that the effect of over-treatment on the cost-effectiveness of either type of test is small because treatment costs are relatively small. For example, if the prevalence of resolved infections was fourfold greater than in Mwanza, then the cost-effectiveness of using POC tests only worsens by 3%. This illustrates that the prevalence of biological false positives or resolved infections is unlikely to be important in deciding whether to use POC or RPR tests in a particular setting, except if there are major negative implications associated with wrongly diagnosing women. However, because of the substantial over-treatment that can occur with either test, care should always be taken in emphasising that the test is

Key messages

- More studies need to be done evaluating the sensitivity of point-of-care (POC) tests for high titre active syphilis (HTAS). However, if the limited data suggesting POC tests have a high sensitivity for HTAS are correct, POC tests could result in similar numbers of “at risk” women being treated for maternal syphilis.
- Unless the cost of available POC tests reduces to below US\$0.63, the rapid plasma reagin (RPR) test is likely to be a more cost-effective option for maternal syphilis screening interventions in well equipped settings with well trained staff such as Mwanza.
- In settings where not all screened women are treated because of delays between testing and treatment, or the RPR test has a lower sensitivity for high titre active syphilis (HTAS) than in Mwanza, then POC tests could improve the cost-effectiveness of maternal syphilis screening interventions. This is likely to include many rural or resource-poor settings.
- Because POC tests are not dependent on expensive equipment or electricity, they could enable the scaling up of maternal syphilis interventions to settings that would otherwise be hard to reach due to operational difficulties in using the RPR test.

being used for screening and would normally require confirmatory testing, but given the potential threat for the unborn child treatment is given even when this cannot be done. This is especially important when treatment strategies also invite partners for treatment.

CONCLUSION

More studies need to be done evaluating the sensitivity of POC tests for HTAS. However, if the limited data suggesting POC tests have a high sensitivity for HTAS are correct, POC tests should be considered as an alternative to the RPR test in many settings. In Mwanza, the Bioline, Visitect and Syphcheck tests are all likely to have resulted in more "at risk" women being treated, and the Bioline test would have cost a similar amount per DALY saved. Indeed, the Bioline test is likely to be more cost-effective than the RPR test in settings where either not all screened women are treated, or the RPR test has a lower sensitivity for HTAS than in Mwanza. This is likely to include many settings where maternal syphilis screening currently takes place,^{5 6 10-13 15 22} and specifically many rural or resource-poor settings. Alternatively, the RPR test is likely to be a better option in well equipped settings with well trained staff. For the other POC tests to be as cost-effective as the RPR test and competitive with the Bioline test, they need to be at least as cheap as the Bioline test or highly sensitive for HTAS. Lastly, because POC tests are not dependent on expensive equipment or electricity, they could enable the scaling up of maternal syphilis interventions to settings that would otherwise be hard to reach due to operational difficulties in using the RPR test. This is an important advantage of POC tests, and their use in low coverage areas should be seen as an important priority for health providers.

ACKNOWLEDGEMENTS

This research was funded by WHO/TDR and the Wellcome Trust. David Mabey, Charlotte Watts, Deborah Watson-Jones and Peter Vickerman also receive funding from the DFID funded AIDS Knowledge Programme. The views expressed are those of the authors and cannot be taken to reflect the official opinion of the London School of Hygiene and Tropical Medicine.

AUTHOR CONTRIBUTIONS

PV participated in the planning of the analysis, collated already published and unpublished data from Mwanza, developed and adapted the impact and cost model for estimating the cost-effectiveness of the POC tests, performed all simulations and sensitivity analysis, interpreted results and wrote the manuscript. FTP, RWP, DM, JC, DWJ and CW all helped in interpreting the model results, and contributed to the manuscript. In addition, FTP, RWP, DM, and CW all helped in planning the analysis, FTP developed the initial cost-effectiveness spreadsheet model, RWP and DM had the initial idea for the study and gave continual expert advice, and JC and DWJ provided published and unpublished data and expertise.



To view appendices 1-6 visit the STI website— <http://www.stijournal.com/supplemental>

Authors' affiliations

P Vickerman, F Terris-Prestholt, J Changalucha, D Mabey, D Watson-Jones, C Watts, London School of Hygiene & Tropical Medicine, London, UK

R W Peeling, Sexually Transmitted Disease Diagnostic Initiative, World Health Organization WHO/TDR, Geneva, Switzerland

Competing interests: none declared

REFERENCES

- 1 **World Health Organisation.** *Global prevalence and incidence of selected curable sexually transmitted infections* (<http://www.who.int/docstore/hiv/grsti/>), Geneva: WHO 2001.
- 2 **Radolf J, Sanchez P, Schultz K.** Congenital syphilis. In: *Sexually transmitted diseases*. Holmes K, Sparling P, Mardh P, et al. New York: McGraw-Hill, 1998.
- 3 **Watson Jones D, Gumodoka B, Weiss H, et al.** Syphilis in pregnancy in Tanzania. II. The effectiveness of antenatal syphilis screening and single-dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. *J Infect Dis* 2002;**186**:948-57.
- 4 **Terris Prestholt F, Watson Jones D, Mugeye K, et al.** Is antenatal syphilis screening still cost effective in sub-Saharan Africa. *Sex Transm Infect* 2003;**79**:375-81.
- 5 **Fonck K, Claeys P, Bashir F, et al.** Syphilis control during pregnancy: effectiveness and sustainability of a decentralized program. *Am J Public Health* 2001;**91**:705-7.
- 6 **Jenniskens F, Obwaka E, Kirisuah S, et al.** Syphilis control in pregnancy: decentralization of screening facilities to primary care level, a demonstration project in Nairobi, Kenya. *Int J Gynaecol Obstet* 1995;**48**(Suppl):S121-8.
- 7 **Temmerman M, Mohamedali F, Franssen L.** Syphilis prevention in pregnancy: an opportunity to improve reproductive and child health in Kenya. *Health Policy and Planning* 1993;**8**:112-7.
- 8 **World Bank.** *World Development Report 1993: investing in health*. New York: Oxford University Press for the World Bank, 1993.
- 9 **Gloyd S, Chai S, Mercer MA.** Antenatal syphilis in sub-Saharan Africa: missed opportunities for mortality reduction. *Health Policy and Planning* 2001;**16**:29-34.
- 10 **Watson Jones D, Oliff M, Terris Prestholt F, et al.** Antenatal syphilis screening in sub-Saharan Africa—lessons learnt from Tanzania. *Trop Med Int Health* 2005;**10**:934-43.
- 11 **Myer L, Wilkinson D, Lombard C, et al.** Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomised controlled trial. *Sex Transm Infect* 2003;**79**:208-13.
- 12 **Rotchford K, Lombard C, Zuma K, et al.** Impact on perinatal mortality of missed opportunities to treat maternal syphilis in rural South Africa: baseline results from a clinic randomized controlled trial. *Trop Med Int Health* 2000;**5**:800-4.
- 13 **West B, Walraven G, Morison L, et al.** Performance of the rapid plasma reagin and the rapid syphilis screening tests in the diagnosis of syphilis in field conditions in rural Africa. *Sex Transm Infect* 2002;**78**:282-5.
- 14 **Patel A, Moodley D, Moodley J.** An evaluation of on-site testing for syphilis. *Trop Doct* 2001;**31**:79-82.
- 15 **Fonn S.** A blood-result turn-around time survey to improve congenital syphilis prevention in a rural area. *S Afr Med J* 1996;**86**:67-71.
- 16 **UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.** *Diagnostics Evaluation Series No.1: Laboratory-based evaluation of rapid syphilis diagnostics*. Geneva: World Health Organisation, 2003.
- 17 **Dorigo-Zetsma JW, Belewu D, Meless H, et al.** Performance of routine syphilis serology in the Ethiopian cohort on HIV/AIDS. *Sex Transm Infect* 2004;**80**:96-9.
- 18 **Gwanzura L, Latif A, Bassett M, et al.** Syphilis serology and HIV infection in Harare, Zimbabwe. *Sex Transm Infect* 1999;**75**:426-430.
- 19 **Changalucha J, Mugeye K, Temu M, et al.** Validity of rapid test results for the diagnosis of syphilis in the clinic setting. *ISSTD*. Amsterdam, Netherlands, 2005.
- 20 **Watson Jones D, Changalucha J, Gumodoka B, et al.** Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. *J Infect Dis* 2002;**186**:940-7.
- 21 **Watson Jones D.** Impact of syphilis on outcome of pregnancy and evaluation of syphilis screening strategies for the reduction of adverse pregnancy outcomes in Mwanza, Tanzania. [PhD Thesis]. London: London School of Hygiene and Tropical Medicine, 2001.
- 22 **Wilkinson D, Wilkinson N, Lombard C, et al.** On-site HIV testing in resource-poor settings: is one rapid test enough? *AIDS* 1997;**11**:377-81.
- 23 **Smikle MF, James OB, Prabhakar P.** Biological false positive serological tests for syphilis in the Jamaican population. *Genitourin Med* 1990;**66**:76-8.
- 24 **Shaw M, van der Sande M, West B, et al.** Prevalence of herpes simplex type 2 and syphilis serology among young adults in a rural Gambian community. *Sex Transm Infect* 2001;**77**:358-65.
- 25 **Todd J, Munguti K, Grosskurth H, et al.** Risk factors for active syphilis and TPHA seroconversion in a rural African population. *Sex Transm Infect* 2001;**77**:37-45.
- 26 **Garcia-Moreno C, Watts CH.** Violence against women: its importance for HIV/AIDS. *AIDS* 2000;**14**(Suppl 3):S253-65.